{"id":"adecatumumab-and-folfox","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Adecatumumab works by binding to EpCAM, a protein expressed on the surface of certain cancer cells, potentially leading to their destruction. FOLFOX, on the other hand, is a combination chemotherapy regimen that targets rapidly dividing cancer cells.","oneSentence":"Adecatumumab is a monoclonal antibody targeting EpCAM, while FOLFOX is a chemotherapy regimen combining oxaliplatin, 5-fluorouracil, and leucovorin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:19:16.426Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer"}]},"trialDetails":[{"nctId":"NCT00866944","phase":"PHASE2","title":"Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases","status":"COMPLETED","sponsor":"Amgen Research (Munich) GmbH","startDate":"2009-03","conditions":"Liver Metastases, Colorectal Cancer","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Adecatumumab and FOLFOX","genericName":"Adecatumumab and FOLFOX","companyName":"Amgen Research (Munich) GmbH","companyId":"amgen-research-munich-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Adecatumumab is a monoclonal antibody targeting EpCAM, while FOLFOX is a chemotherapy regimen combining oxaliplatin, 5-fluorouracil, and leucovorin. Used for Colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}